Enterprise Value

-35.39M

Cash

54.32M

Avg Qtr Burn

-9.767M

Short % of Float

0.51%

Insider Ownership

8.61%

Institutional Own.

17.78%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ONCT-808 (CAR-T) Details
Solid tumor/s, Hematologic malignancies, Cancer

Phase 1/2

Data readout

ONCT-534 Details
Cancer, Castration-resistant prostate cancer

IND

Submission

Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details
Blood cancer, Chronic lymphocytic leukemia, Cancer, Mantle cell lymphoma

Failed

Discontinued

Failed

Discontinued

ONCT-216 (TK216) (EWS-FLI1 inhibitor) Details
Relapsed/refractory Ewing sarcoma, Cancer

Failed

Discontinued

Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details
Blood cancer, Cancer, Mantle cell lymphoma

Failed

Discontinued